|
|
| (9 intermediate revisions by 4 users not shown) |
| Line 1: |
Line 1: |
| ==Background==
| | #REDIRECT[[Eosinophilic granulomatosis with polyangiitis]] |
| *Eosinophilic granulomatosis with polyangiitis (EGPA)
| |
| *Chronic sinusitis, asthma, and peripheral eosinophilia
| |
| *Vasculitis of small and medium sized vessels
| |
| *Lung and skin are most commonly involved
| |
| | |
| ==Clinical Features==
| |
| *Classically develops in three sequential phases
| |
| | |
| *Prodrome
| |
| **Atopic diseases, allergic rhinitis, and asthma
| |
| | |
| *Eosinophilic phase
| |
| **Multiorgan involvement, particularly lung and GI tract
| |
| **Caused by eosinophilic infiltration into these organs
| |
| | |
| *Vasculitic phase
| |
| **Life threatening vasculitis associated with vascular and extravascular granulomatosis
| |
| **May present with nonspecific signs such as fever, weight loss, malaise
| |
| | |
| ==Differential Diagnosis==
| |
| *Aspirin-exacerbated respiratory disease
| |
| *Chronic eosinophilic pneumonia
| |
| *Allergic bronchopulmonary aspergillosis
| |
| *Hypereosinophilic syndrome
| |
| *Other vasculitides
| |
| | |
| ==Diagnosis==
| |
| *Typically a clinical diagnosis
| |
| *Labs with elevated eosinophils, ESR, CRP, ANCA
| |
| *CXR with transient, patchy opacities
| |
| | |
| ==Management==
| |
| *Initiation Therapy
| |
| **Prednisone 0.5-1.5 mg/kg/day
| |
| **Cyclophosphamide
| |
| | |
| *Maintenance Therapy
| |
| **Azathioprine
| |
| **Methotrexate
| |
| **Leflunomide
| |
| **Inhaled glucocorticoids
| |
| | |
| ==Disposition==
| |
| *Refer to rheumatology
| |
| | |
| ==See Also==
| |
| | |
| ==External Links==
| |
| | |
| ==References==
| |
| <UpToDate>
| |
